Success Metrics

Clinical Success Rate
88.0%

Based on 22 completed trials

Completion Rate
88%(22/25)
Active Trials
0(0%)
Results Posted
18%(4 trials)
Terminated
3(10%)

Phase Distribution

Ph early_phase_1
1
3%
Ph not_applicable
1
3%
Ph phase_2
7
24%
Ph phase_3
5
17%
Ph phase_4
12
41%

Phase Distribution

1

Early Stage

7

Mid Stage

17

Late Stage

Phase Distribution26 total trials
Early Phase 1First-in-human
1(3.8%)
Phase 2Efficacy & side effects
7(26.9%)
Phase 3Large-scale testing
5(19.2%)
Phase 4Post-market surveillance
12(46.2%)
N/ANon-phased studies
1(3.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.5%

22 of 27 finished

Non-Completion Rate

18.5%

5 ended early

Currently Active

0

trials recruiting

Total Trials

29

all time

Status Distribution
Completed(22)
Terminated(5)
Other(2)

Detailed Status

Completed22
Terminated3
Withdrawn2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
29
Active
0
Success Rate
88.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.8%)
Phase 27 (26.9%)
Phase 35 (19.2%)
Phase 412 (46.2%)
N/A1 (3.8%)

Trials by Status

withdrawn27%
terminated310%
completed2276%
unknown27%

Recent Activity

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more
NCT03510884Phase 3

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Completed
NCT03510715Phase 3

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Completed
NCT04285749Early Phase 1

Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas

Withdrawn
NCT00404287Phase 4

Randomized Study to Evaluate the Efficacy of Fluvastatin on Inflammatory Markers in Patients With Aortic Stenosis.

Terminated
NCT03189511Phase 4

Effect of Fluvastatin on Brown Fat Activity

Completed
NCT00674297Phase 2

Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients

Completed
NCT01992042Phase 2

Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer

Completed
NCT00125125Phase 4

Fluvastatin in Adults With Dislipidemia With History of Muscle Problems

Completed
NCT00821574Phase 4

Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome

Completed
NCT00171262Phase 4

Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers

Completed
NCT00138528Phase 4

Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome

Completed
NCT00136799Phase 3

Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia

Completed
NCT00565474Phase 4

Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant

Completed
NCT02518516

High Potency Statins and Acute Kidney Injury

Completed
NCT02518503

High Potency Statins and the Risk of Diabetes

Completed
NCT01045512Phase 2

The Role of the "Inflammatory/ Pathogen Burden" for Cardiac Ageing

Terminated
NCT00814606Phase 2

A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C

Withdrawn
NCT00487318Phase 2

Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin

Completed
NCT00441493Not Applicable

Fluvastatin Versus Hepatitis C Virus

Completed
NCT00171236Phase 3

Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia

Completed

Drug Details

Intervention Type
DRUG
Total Trials
29